Skip to content

Hyperbaric Oxygen Therapy for Post-Stroke Depression: A Study on Predicting Treatment Efficacy in Advance Using Multi-Omics Technology

Construction and Validation of a Predictive Model for the Efficacy of Hyperbaric Oxygen Therapy in Post-Stroke Depression Based on Multi-Omics Integration Analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600124341
Enrollment
Unknown
Registered
2026-05-11
Start date
2026-05-11
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-stroke depression (PSD)

Interventions

sham stimulation control group:In-bore simulation treatment
conventional neurological rehabilitation treatment.
Hyperbaric oxygen therapy group
sham stimulation control group.:Hyperbaric oxygen therapy

Sponsors

Affiliated Kangning Hospital of Ningbo University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18–75 years; 2. First-ever acute ischemic or hemorrhagic stroke confirmed by CT or MRI; 3. Meeting the diagnostic criteria for "depressive disorder due to another medical condition" according to the Diagnostic and Statistical Manual of Mental Disorders (5th edition) (DSM-5); 4. Hamilton Depression Rating Scale (HAMD-17) score >= 17, indicating at least moderate depression; 5. The patient or their legal representative has understood and voluntarily signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Severe aphasia, sensory aphasia, severe cognitive impairment (MMSE score = 3 on item 3 (suicidal ideation) of the HAMD scale, or a clear and urgent risk of self-harm or suicide as clinically assessed by the investigator; 5. Absolute contraindications to hyperbaric oxygen therapy such as untreated pneumothorax, severe emphysema, or active tuberculosis; 6. Severe cardiac, hepatic, or renal insufficiency (laboratory values > 1.5 times the upper limit of normal), or an expected survival of less than one year.

Design outcomes

Primary

MeasureTime frame
Hamilton Depression Rating Scale.;

Secondary

MeasureTime frame
Improvement in quality of life;Improvement in daily living abilities;Improvement of cognitive function;

Countries

China

Contacts

Public ContactYang Mei

Affiliated Kangning Hospital of Ningbo University

1158126680@qq.com+86 574 2630 2554

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026